fbpx
Artboard 2

First and Only FDA Cleared AI-Based Prostate Cancer Decision Support Platform

FDA cleared

NOV 2022

Cleared by the FDA for AI-Based Decision Support

FDA awarded

MAY 2021

Granted Breakthrough Device Designation by the FDA

Check logo

AUG 2023

Stanford Study Validated Accuracy and Effectiveness of Unfold AI

21972-312_SOC_NonCPA

AUG 2023

SOC2 Compliant

A New Superpower For Doctors

Tumorracterization
Tumorracterization

Unfold AI combines patient specific data and deep learning algorithms to create a unique personalized cancer estimation map that visualizes the size and extent of cancer in 3D

Are you a doctor interested in learning about how Unfold AI can be incorporated into your practice?

Clinically Validated Performance Beyond the Standard of Care

Clinical-Data-Slide_23FEB2024.pptx-6

Unfold AI Research Highlights

Cancer Mapping and Treatment Success

Unfold AI was used to predict the extent of tumors in surgically removed prostate specimens. It predicted tumor margins more accurately than conventional methods.

This approach could improve and standardize treatment margin definition, potentially reducing cancer recurrence rates. Furthermore, an accurate assessment of negative margin probability could facilitate informed decision-making for patients and doctors.

    • The average sensitivity of detecting cancer was higher for AI (97%) than for radiologists (37%)
    • For index lesions, Unfold AI margins were more often negative (90%) than conventional ROIs (0%, p < 0.001), 10-mm ROI margins (82%, p = 0.24), and hemigland margins (66%, p = 0.004).

Read full paper here

Encapsulation
Extracapsular Extension Prediction
Tumor Volume
Encapsulation Confidence Score​

Include Unfold AI in your Patient's Prostate Cancer Care

Physician Timeline-Website (4)
Vertical physician journey

Are you a doctor interested in learning about how Unfold AI can be incorporated into your practice?